Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased AEterna Zentaris, Inc. (“AEterna” or the “Company”) (Nasdaq: AEZS) securities between February 3, 2010 and April 1, 2012 (the “Class Period”).
For more information, click here: http://zlk.9nl.com/aeterna-zentaris-aezs. There is no cost or obligation to you.
The complaint alleges that AEterna and certain of its executive officers misrepresented and/or failed to accurately disclose material information about the prospects of perifosine, its development-stage colon cancer drug. On April 2, 2012 the Company announced that phase 3 clinical trials showed that perifosine administered with capecitabine was no more effective than capecitabine administered with a placebo in patients with refractory advanced colorectal cancer. Upon this news, shares of AEterna plummeted, from a closing price of $2.14 per share on March 30, 2012 to just $0.73 per share on April 2, 2012.
If you suffered a loss in AEterna you have until August 14, 2012 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (877) 363-5972, or visit http://zlk.9nl.com/aeterna-zentaris-aezs.Levi & Korsinsky is a national firm with offices in New York and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts